Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Convertible Debt: 2009-2021

Historic Convertible Debt for Northwest Biotherapeutics (NWBO) over the last 10 years, with Dec 2021 value amounting to $300,000.

  • Northwest Biotherapeutics' Convertible Debt changed negligibly% to $300,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $300,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $300,000 for FY2021, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2021, Northwest Biotherapeutics' Convertible Debt is $300,000, which was down 0.00% from $300,000 recorded in FY2020.
  • In the past 5 years, Northwest Biotherapeutics' Convertible Debt ranged from a high of $6.0 million in FY2017 and a low of $300,000 during FY2020.
  • Moreover, its 2-year median value for Convertible Debt was $300,000 (2021), whereas its average is $300,000.